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A revolution in the basic science related to plants has occurred over the last
fifteen years as techniques for genetic engineering have been developed. It is
now possible to introduce foreign genes into almost all major crops, resulting
in stable genetic transformants that pass the new trait on to their progeny
following the principles of Mendelian genetics. Those protocols have led to
detailed understanding of the mechanisms by which gene expression is regu-
lated in the different tissues, and at different times, in the plant life cycle. From
an applied standpoint, this understanding can be used to cause foreign genes to
be expressed only in selected tissues — such as fruits or grains. Plant biotech-
nology has yielded commercial products in the field of agriculture as plants
resistant to insects, viruses, fungi, and herbicides have been created. In addition,
foods with modified ripening characteristics are now commercially available.
Beginning in the last few years, various research laboratories have experi-
mented with the use of plants for “biomanufacturing” of specialty products.
These approaches utilize transgenic plants created to accumulate high value
proteins/enzymes. Some of those studies have explored the production of
proteins of potential pharmaceutical value. It has been shown that plants will
produce molecules as diverse as human serum albumin (which requires exten-
sive conformation folding) and both serum and secretory antibodies (which
require assembly of multiple peptide subunits to produce a functional antibody).
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EXPRESSION OF ANTIGENIC PROTEINS IN TRANSGENIC PLANTS
It has been well documented that molecular biology has had enormous impact
on the fields of immunology and vaccine development. Tools to identify and
clone the genes encoding antigenic determinants of infectious agents have
been developed and are in wide use. The introduction of the gene encoding
the surface antigen of the hepatitis B virus (HBV) in recombinant yeast was the
first commercial example of a recombinant subunit vaccine. The HBV vaccine
produced by recombinant DNA techniques is extremely safe and effective;
however, its high cost has led the Institute of Medicine to list the development
of a lower-cost recombinant DNA vaccine as a top priority. It can be readily
anticipated that numerous other recombinant subunit vaccines will also become
available in the next decade as our understanding of immune recognition of
individual proteins grows. While these offer exciting opportunities for disease
prevention, dependence upon fermentation technology and protein purification
will influence both cost and availability of the new vaccines to the developing
world. This led us to explore the use of transgenic plants as a subunit vaccine
expression system.
HEPATITIS B SURFACE ANTIGEN EXPRESSION IN PLANTS
We began our studies of candidate vaccine expression in transgenic plants using
the gene encoding hepatitis B surface antigen (HBsAg). This protein was chosen
because the commercially available vaccine and the associated human immune
response have been very well characterized, because the structure of the immu-
nogenic form of that protein was known, and because the availability of a cost-
effective recombinant HBV vaccine for the developing world is a high priority.
In our initial studies, the gene for HBsAg was introduced into cells of tobacco
plants and individual transgenic plants were regenerated. We chose tobacco
for the experiments because of its ease of genetic manipulation and abundant
literature on controls for gene expression in this facile “model laboratory
plant.” When transgenic leaf material was extracted, virus-like particles could
be recovered. These were characterized and were found to be very similar in
structural properties to the recombinant HBsAg, which is formulated in the
commercial vaccine produced in yeast cells.
When plant-derived HBsAg was used for parenteral immunization of mice,
anti-HBsAg antibodies were recovered that reacted with authentic HBsAg from
human serum. This was our first indication that antigenic properties of the
protein were maintained in recombinant plants. Subsequently, T-cells were
isolated from mice immunized with tobacco-derived HBsAg. When grown in
culture, these T-cells could be activated using the commercial vaccine, as well
as a synthetic peptide that mimics the “a” epitope determinant of HBsAg. In
total, the immunology studies conducted to date show that the recombinant
HBsAg recovered from plant cells retains both B- and T-cell epitopes. These
studies have demonstrated that plant cells have the capacity to not only synthe-
size this protein but to allow it to assemble in an immunologically active form.
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VACCINES AGAINST BACTERIAL DIARRHEAL DISEASE
Diarrheal disease is the major cause of infant mortality on a worldwide basis.
Vaccines to prevent diarrheal disease caused by bacteria or viruses could have a
significant impact on human health in the developing world. As my colleagues
and I had an interest in testing the oral immunogenicity of recombinant anti-
gens produced in plants, we made an early choice to focus on enteric diseases.
The binding subunit of the heat-labile enterotoxin of E. coli (LT-B) was an
obvious candidate for evaluation in plant expression systems since it has been
extensively characterized in structural and immunological studies. Because it
is very similar in structure and immunological properties to the B-subunit of
cholera toxin (CT-B), immunization with CT-B leads to cross protection against
enterotoxigenic E. coli (ETEC). Early field studies of cholera vaccines in
Bangladesh showed that CT-B immunization was useful in preventing cholera,
although protection was relatively short lived and protective immunity would
require frequent boosting.
Our initial studies utilized an expression vector that caused the production
of recombinant LT-B in transgenic plants using the native bacterial gene.
Characterization of this protein was hampered by the low amount of protein
that accumulated in the plants. Subsequently, the bacterial gene was modified
to encode a fusion protein, which has a six amino-acid microsomal retention
signal at the C-terminus of LT-B. We reasoned that retention of the newly
synthesized LT-B in microsomal vesicles of plant cells would allow an increase
in the relative concentration of the protein, leading to assembly of the active
pentameric form of LT-B. We found that higher amounts of LT-B accumulated,
and it could be isolated for characterization. Based on its physical properties
and its ability to bind GM1 gangliosides, we determined that the LT-B fusion
protein assembled into the active oligomeric structure within plant cells. When
this protein was partially purified from transgenic plants and given by oral
gavage to mice, both serum and secretory antibodies that were specific for LT-B
could be recovered from the treated animals. These antibodies were effective
in inactivating the E. coli toxin when tested using in vitro assays as an indicator
of protective immunity.
My colleagues and I are continuing our efforts to create transgenic plants that
accumulate abundant amounts of recombinant LT-B in edible tissues. We have
been guided by the earlier CT-B vaccine field trials that used one milligram of
protein per oral dose. By creating a synthetic gene that encodes an LT-B protein
of the authentic amino acid sequence, but uses codons which are preferred by
plants, we have recently been successful in creating plants that accumulate
one milligram of LT-B in a potato that could be consumed raw by a human
volunteer. We are cooperating with John Clements of the Tulane Medical
School, as well as Michael Levine and Carol Tackett of the Center for Vaccine
Development at the University of Maryland, to evaluate this material in human
clinical trials for feasibility of use as an oral vaccine.
VACCINES AGAINST VIRAL DIARRHEAL DISEASE
Multiple viruses cause diarrheal disease. Rotavirus may be the principal agent,
especially in infants. As we began studies of the potential value of transgenic
plants to produce recombinant subunit vaccines, I consulted with Dr. Mary
Estes of the Baylor College of Medicine about the potential for a plant-based
vaccine for rotavirus. From the data she provided, we concluded that coor-
dinate expression of at least two (and possibly more) rotavirus coat proteins
might be needed to cause the assembly of an immunogenic virus-like particle.
Since we had not yet evaluated the capacity of transgenic plants to produce
immunogenic proteins and because coordinate expression of multiple foreign
proteins in plants had not been characterized, we concluded that a simpler
system was needed that would provide “proof of principle.” For this system we
turned to the characterization of a candidate vaccine against Norwalk virus.
Norwalk virus (NV) is a member of the Caliciviridae family. It is a causal
agent of severe epidemic outbreaks of viral diarrhea. When the gene encoding
the single capsid protein of Norwalk virus was expressed in insect cells, virus-
like particles (VLPs) could be isolated. These particles were also found to be
effective in causing oral immunization of mice, resulting in production of
both serum and antibody specific for the capsid protein. Unfortunately, there
is no animal model to demonstrate protective immunity of vaccines against
the Norwalk virus; those determinations will require human clinical trials.
Extracts of plants expressing the NV capsid protein were found to contain
VLPs that mimicked the structural properties of VLPs recovered from insect
cells. When these were partially purified and given to mice by gavage, both
serum and secretory antibodies to the NV capsid protein were produced.
ORAL IMMUNIZATION USING EDIBLE PLANT TISSUES
Although our initial subunit vaccine experiments used tobacco as a test system,
our goal was to produce candidate vaccines in edible plant tissue to evaluate
the potential for immunization simply by eating the tissue. Because the oral
immunogenicity of plant-derived antigens had been demonstrated by the oral
gavage studies, we developed protocols for genetic transformation of potato
using genetic regulatory elements that cause the accumulation of the desired
recombinant protein in the potato tuber tissues. We chose potatoes for two
reasons. First, we could recover transgenic plants and grow them to maturity in
greenhouses in a relatively short period (about three to four months). Secondly,
mice will readily eat raw potatoes.
Transgenic plant material has been generated that contains both recombinant
LT-B and the recombinant Norwalk virus capsid protein. The proteins assem-
bled into the appropriate structures (LT-B pentamers that bound GM1 ganglio-
sides, or VLPs for the NV capsid protein). Potatoes were peeled, and five gram
samples were fed to mice on a schedule that was analogous to the previous
experiments using gavage for oral immunization. In both cases, the mice
produced serum and secretory antibodies against the recombinant protein in
the potato eaten by the mice as food. These studies provide “proof of concept”
for edible vaccines.
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Figure 1. A schematic diagram showing the steps involved in creating transgenic plants expressing
immunogenic proteins. A. Based upon earlier immunology studies, a candidate antigen with
known or potential value as a subunit vaccine is identified. B. The structural gene encoding the
antigen of interest is obtained or isolated. C. The gene is ligated into a plant transformation vector
which contains plant-specific promoter and terminator sequences to regulate gene expression.
D. The natural gene transfer system of Agrobacterium tumefaciens is usually utilized to mobilize the
genetic construct into the chromosomes of plant cells. E. Plants are regenerated from transformed
cells that contain a stably integrated gene encoding the desired antigen. F. and G. Immunogenicity
of the plant-expressed antigen is determined by either extracting the foreign protein and delivering
it by parenteral or oral routes, or simply by feeding a plant sample as food.
VACCINES FOR ANIMAL DISEASES
Oral vaccines can provide efficient and humane strategies for disease prevention
in production and companion animals, as well as feral populations. The above-
mentioned “proof of concept” for edible vaccines suggests that the design of
subunit vaccines in feed crops is a viable strategy. Seed-specific genetic regu-
latory elements are known for crops such as corn and soybeans, and stability
of foreign proteins in dried seeds has been demonstrated.
Recently, transgenic plants have been generated that expressed the gene
encoding the glycoprotein (G-protein), which coats the outer surface of the
rabies virus. Although the immunogenicity of these materials has yet to be
reported, it is encouraging to note that bait containing some G-protein pro-
duced in a more traditional in-vitro system was effective in orally immunizing
raccoons, providing protection against “street virus” challenge.
REMAINING QUESTIONS/OPPORTUNITIES FOR EDIBLE VACCINES IN
TRANSGENIC PLANTS
The research conducted to date has demonstrated that transgenic plants have
the capacity to synthesize and accumulate subunit antigenic proteins that retain
immunological properties of their native counterparts. In the case of the HBsAg
and the NV-capsid protein, virus-like particles accumulate; this may be very
significant because the particulate form of the proteins is likely to be important
in determining immunogenic properties. It is likely that particulate structures
will have greater oral immunogenicity than soluble proteins.
Studies not yet conducted will involve the evaluation of dosage requirements
for plant-delivered vaccines. Successful experiments conducted thus far have
used proteins from two enteric organisms. It will be necessary to determine if
other proteins, which may not be normally transmitted via the oral route, will
be as effective in inducing an oral immune response. We are optimistic, how-
ever, because plant cells represent a natural bioencapsulation system with
surrounding layers of cell wall, cell membrane, and (in some cases) internal
membrane compartments to encapsulate and thereby protect the desired
subunit protein from digestive degradation. It remains to be determined if
the release of the desired protein in the gut acts as a “slow release” as the plant
cells are degraded in the normal digestive process. If so, dosage levels may have
to be adjusted accordingly.
A potential major advantage of recombinant plants for vaccine production is
the possibility that multi-subunit vaccines, including an oral adjuvant such as
CT or LT (or derivatives thereof) could all be produced in a single plant. There
is no theoretical limit to the number of different genes that could be introduced
into a single plant species. Plant tissue could, therefore, contain multiple anti-
gens in one delivery system. In addition, this could circumvent the need for a
cold chain in vaccine delivery when produced and utilized in developing countries.
It is well recognized that most food proteins do not trigger an immune
response; in general this is due to the induction of a state of immune tolerance.
It will be necessary to determine if food-based vaccines will also induce oral
tolerance to the desired antigen. If so, controlled use and dosage will be a
requirement for “edible vaccines.” This should not be an insurmountable
obstacle, however, as only a small amount of plant material would need to be
propagated for wide-scale vaccine delivery and its distribution could become
a component of public health care systems.
The type of plant material that would best serve as an “edible vaccine” is yet
to be determined. For human vaccines, our own research team has focused on
the use of bananas. This crop has three major attributes: it is grown in almost
all tropical or sub-tropical developing countries throughout the world; the food
is eaten uncooked (which would avoid denaturation of subunit proteins); and
bananas are a food that is widely consumed by infants and children. At the
present time, we have developed a methodology for the genetic transformation
of bananas and are cloning fruit-specific genetic regulatory elements, which
we believe will cause the tissue-specific production of the desired candidate
vaccine in the developing fruit. The primary disadvantage of bananas is one of
technical limitations during feasibility stages of research. This is due to the fact
that the time from genetic transformation until harvest and evaluation of the
fruit is relatively long. We anticipate that the time period will be at least two
years. Our first transgenic banana plants containing genes encoding candidate
vaccines are still in the seedling stage.
For animal vaccines, a variety of grain crops (such as soybeans or corn) rep-
resent excellent possibilities for vaccine delivery. Transformation techniques
for those crops are known, as are strategies for causing seed-specific gene
expression.
In summary, the expression of vaccines in plants may be the first large-scale
example of production of high-value pharmaceuticals in transgenic crops.
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